Clinical Trial Update: Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes [Phase 3]

View source ↗

Summary

Phase 3 trial comparing erythropoietin with or without filgrastim to supportive therapy alone in myelodysplastic syndromes; results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelodysplastic Syndromes

Drugs mentioned

• Erythropoietin (erythropoietin)
• Filgrastim (filgrastim)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Anemia, Myelodysplastic Syndromes | Phase 3 | Status: COMPLETED | Results posted: 2013-12-06